Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.34 |
| ▸ | GRM5 | P41594 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12210478 | 0.82 | HDAC6 (0.57) | HDAC6GRM5 | |
| SCHEMBL12210475 | 0.79 | HDAC6 (0.54) | HDAC6RIPK1GRM5 | |
| SCHEMBL12210493 | 0.77 | HDAC6 (0.52) | HDAC6GRM5 | |
| SCHEMBL12210531 | 0.77 | HDAC6 (0.60) | HDAC6RIPK1GRM5 | |
| SCHEMBL12210581 | 0.70 | HDAC6 (0.45) | HDAC6RIPK1GRM5 | |
| SCHEMBL12210532 | 0.69 | HDAC6 (0.53) | HDAC6GRM5 | |
| SCHEMBL2526693 | 0.68 | HDAC6 (0.55) | HDAC6GRM5 | |
| SCHEMBL12210588 | 0.68 | HDAC6 (1.00) | HDAC6GRM5 | |
| SCHEMBL12285743 | 0.68 | HDAC6 (0.52) | HDAC6RIPK1GRM5 | |
| SCHEMBL12210483 | 0.68 | HDAC6 (0.67) | HDAC6GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | claimed |
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2011130163-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | HDAC6 1/4885RIPK1 2631/4885EPHX2 2094/4885 |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | HDAC6 1/4885RIPK1 2631/4885EPHX2 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.